EA201070228A1 - Тразодон и гидрохлорид тразодона в очищенной форме - Google Patents

Тразодон и гидрохлорид тразодона в очищенной форме

Info

Publication number
EA201070228A1
EA201070228A1 EA201070228A EA201070228A EA201070228A1 EA 201070228 A1 EA201070228 A1 EA 201070228A1 EA 201070228 A EA201070228 A EA 201070228A EA 201070228 A EA201070228 A EA 201070228A EA 201070228 A1 EA201070228 A1 EA 201070228A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trazodone
hydrochloride
trazodone hydrochloride
trazodon
purified form
Prior art date
Application number
EA201070228A
Other languages
English (en)
Other versions
EA017019B1 (ru
Inventor
Марчелло Маркетти
Томмазо Иакоанджелли
Джованни Баттиста Чоттоли
Джузеппе Бьонди
Original Assignee
Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39064326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070228(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. filed Critical Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.
Publication of EA201070228A1 publication Critical patent/EA201070228A1/ru
Publication of EA017019B1 publication Critical patent/EA017019B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Способ получения тразодона или гидрохлорида тразодона, который включает стадии: (а) приготовления органической фазы, включающей тразодон, по меньшей мере в одном органическом растворителе; (b) приготовления водной фазы, включающей по меньшей мере одно основное соединение; (с) смешения указанной водной фазы с указанной органической фазой; (d) нагревания при температуре по меньшей мере 40°С в течение по меньшей мере 30 мин; (е) извлечения указанного тразодона и, необязательно, (f) обработки указанного тразодона хлористо-водородной кислотой для получения гидрохлорида тразодона. Тразодон или гидрохлорид тразодона, включающие менее 15 ppm алкилирующих веществ, и фармацевтическая композиция, включающая указанный гидрохлорид тразодона.
EA201070228A 2007-08-03 2008-07-23 Тразодон и гидрохлорид тразодона в очищенной форме EA017019B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001603A ITMI20071603A1 (it) 2007-08-03 2007-08-03 Trazodone e trazodone cloridrato in forma purificata
US97653507P 2007-10-01 2007-10-01
PCT/EP2008/059640 WO2009019133A1 (en) 2007-08-03 2008-07-23 Trazodone and trazodone hydrochloride in purified form

Publications (2)

Publication Number Publication Date
EA201070228A1 true EA201070228A1 (ru) 2010-06-30
EA017019B1 EA017019B1 (ru) 2012-09-28

Family

ID=39064326

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070228A EA017019B1 (ru) 2007-08-03 2008-07-23 Тразодон и гидрохлорид тразодона в очищенной форме

Country Status (23)

Country Link
US (19) US8133893B2 (ru)
EP (1) EP2178850B1 (ru)
JP (3) JP5635401B2 (ru)
KR (2) KR20140133901A (ru)
CN (1) CN101772490B (ru)
AR (1) AR067773A1 (ru)
BR (1) BRPI0814448B8 (ru)
CA (1) CA2693095C (ru)
CY (1) CY1115666T1 (ru)
DK (1) DK2178850T3 (ru)
EA (1) EA017019B1 (ru)
ES (1) ES2517871T3 (ru)
GE (2) GEP20135926B (ru)
HK (1) HK1139405A1 (ru)
HR (1) HRP20140978T1 (ru)
IL (2) IL203294A (ru)
IT (1) ITMI20071603A1 (ru)
MX (1) MX2010001094A (ru)
PL (1) PL2178850T3 (ru)
PT (1) PT2178850E (ru)
SI (1) SI2178850T1 (ru)
UA (1) UA103597C2 (ru)
WO (1) WO2009019133A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071573A1 (it) 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) * 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
CN103853790B (zh) * 2012-12-06 2016-04-06 腾讯科技（深圳）有限公司 移动终端浏览器的上传信息处理方法及装置
IN2014MU00203A (ru) * 2014-01-21 2015-09-25 Piramal Entpr Ltd
CN105777745A (zh) * 2016-03-29 2016-07-20 深圳市泛谷药业股份有限公司 一种盐酸曲唑酮的制备方法
DK3749668T3 (da) * 2018-02-07 2022-06-20 Acraf Kontinuerlig fremgangsmåde til fremstilling af trazodonbase
RU2706700C1 (ru) 2019-09-24 2019-11-20 Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" Фармацевтическая композиция для коррекции поведения кошек и собак в стрессовых ситуациях
CN117517545A (zh) * 2023-12-08 2024-02-06 重庆锐恩医药有限公司 一种盐酸曲唑酮有关物质检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8135E (ru)
GB1117068A (en) * 1965-12-15 1968-06-12 Acraf S-triazole-[4,3-a]-pyridine derivatives and processes for their preparation
IT1066857B (it) 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
FR8135M (ru) * 1968-12-31 1970-08-10
IT1047702B (it) * 1975-07-24 1980-10-20 Acraf Nuova sintesi degli psicofarmaci denominati trazodone ed eteroperidone
US4465683A (en) * 1979-09-14 1984-08-14 Mead Johnson & Company Anti-psychotic agents
US4254124A (en) * 1979-09-24 1981-03-03 Mead Johnson & Company Antidepressant agent
US4252806A (en) * 1979-09-24 1981-02-24 Mead Johnson & Company Triazoloquinolones
IT1211095B (it) * 1981-08-17 1989-09-29 Roma Aziende Chimiche Riunite Impiego del trazodone nel trattamento delle ulcere gastroduodenali.
IT1233412B (it) * 1987-12-02 1992-03-30 Acraf Uso del trazodone
IT1314283B1 (it) * 1999-12-16 2002-12-06 Acraf Trazodone cloridrato ed un procedimento per prepararlo.
EA008705B1 (ru) * 2003-04-08 2007-06-29 Алгоркс Фармасьютикалз, Инк. Получение и очистка синтетического капсаицина
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
ITMI20071573A1 (it) 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) * 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata

Also Published As

Publication number Publication date
GEP20135926B (en) 2013-10-10
US20210052577A1 (en) 2021-02-25
US20100056539A1 (en) 2010-03-04
PT2178850E (pt) 2014-10-07
BRPI0814448A2 (pt) 2016-07-26
ES2517871T3 (es) 2014-11-04
EP2178850B1 (en) 2014-09-03
DK2178850T3 (en) 2014-11-17
BRPI0814448B8 (pt) 2021-05-25
IL203294A (en) 2013-05-30
US20160113926A1 (en) 2016-04-28
US20180353503A1 (en) 2018-12-13
BRPI0814448B1 (pt) 2019-04-02
JP2010535170A (ja) 2010-11-18
US20150105402A1 (en) 2015-04-16
CA2693095C (en) 2015-11-24
US20130203771A1 (en) 2013-08-08
US20170128442A1 (en) 2017-05-11
AU2008285779A1 (en) 2009-02-12
US20120142699A1 (en) 2012-06-07
KR101505522B1 (ko) 2015-03-30
CN101772490A (zh) 2010-07-07
KR20100046245A (ko) 2010-05-06
EA017019B1 (ru) 2012-09-28
US8133893B2 (en) 2012-03-13
WO2009019133A1 (en) 2009-02-12
CN101772490B (zh) 2013-11-06
US8314236B2 (en) 2012-11-20
CY1115666T1 (el) 2017-01-25
IL225873A (en) 2016-10-31
US20160324853A1 (en) 2016-11-10
US20130012520A1 (en) 2013-01-10
CA2693095A1 (en) 2009-02-12
US20200253965A1 (en) 2020-08-13
AR067773A1 (es) 2009-10-21
US20150297589A1 (en) 2015-10-22
US20190231774A1 (en) 2019-08-01
JP2014221788A (ja) 2014-11-27
JP6513911B2 (ja) 2019-05-15
MX2010001094A (es) 2010-03-01
US20240139179A1 (en) 2024-05-02
US20200038396A1 (en) 2020-02-06
US20140057922A1 (en) 2014-02-27
KR20140133901A (ko) 2014-11-20
JP5635401B2 (ja) 2014-12-03
HRP20140978T1 (hr) 2014-12-05
SI2178850T1 (sl) 2014-12-31
HK1139405A1 (en) 2010-09-17
UA103597C2 (en) 2013-11-11
US20180161323A1 (en) 2018-06-14
JP2017141246A (ja) 2017-08-17
IL225873A0 (en) 2013-06-27
GEP20135915B (en) 2013-08-26
ITMI20071603A1 (it) 2009-02-04
US20140296250A1 (en) 2014-10-02
US20170333425A1 (en) 2017-11-23
PL2178850T3 (pl) 2015-03-31
EP2178850A1 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
EA201070228A1 (ru) Тразодон и гидрохлорид тразодона в очищенной форме
AR067775A1 (es) (2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de uso
BRPI0906786A2 (pt) Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
EA201170772A1 (ru) Органические соединения
NO20085004L (no) Radioaktivt merkede dihydrotetrabenazinderivater og deres anvendelse som avbildningsmidler
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA200801833A1 (ru) Способы получения кристаллических форм дулоксетина гидрохлорида
EA201170524A1 (ru) Урацилсодержащие соединения и гербициды, включающие такие соединения
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
BRPI0508969A (pt) compostos orgánicos
BRPI0815750A2 (pt) processo para recuperar um solvente orgânico e um etanol orgânico de uma mistura de etanol/água.
BRPI0811275A2 (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
ATE539054T1 (de) Verfahren zur herstellung von dihydropyrrolderivaten als zwischenprodukte
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
BRPI0817721A2 (pt) Composto, composição farmacêutica, método de tratamento, e, processo para preparação de um composto
UY29498A1 (es) Derivados de aminoácidos
DK1907396T3 (da) Fremgangsmåde til fremstilling af 4-beta-amino-4'-demethyl-4-deoxypodophyllotoxin
BR112015028740A2 (pt) processo para preparar dicarbamatos de 1,4:3,6-dianidroexitóis, composto químico precursor, composto químico derivado a partir de pelo menos um dos compostos químicos precursores, e, método de preparação de um composto químico derivado a partir de pelo menos um dos compostos químicos precursores
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
DE602006014001D1 (de) Herstellung von 2-aminothiazol-5-carbonsäurederivaten

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM